이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Comparison of Postoperative Recovery Quality and Safety Between Anricofen Combined With Ciprofol and Sufentanil Combined With Ciprofol for Non-intubated Anesthesia During ERCP (Anricofen Cipr)

Comparison of Postoperative Recovery Quality and Safety Between Anricofen Combined With Ciprofol and Sufentanil Combined With Ciprofol for Non-intubated Anesthesia During Endoscopic Retrograde Cholangiopancreatography: A Randomized Controlled Trial

This study aims to compare postoperative recovery quality and safety between anricofen combined with ciprofol and sufentanil combined with ciprofol in patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) under non-intubated anesthesia.

This is a single-center, prospective, randomized, controlled study involving patients aged 18-80 years who are scheduled for elective ERCP. A total of 180 participants are planned to be enrolled and randomly assigned in a 1:1 ratio to two groups.

Participants in the anricofen group will receive intravenous anricofen (HSK21542) at a dose of 1 μg/kg before ciprofol induction. Participants in the sufentanil group will receive intravenous sufentanil at a dose of 0.1 μg/kg before ciprofol induction. Both groups will receive ciprofol for anesthesia induction and maintenance.

The primary outcome is the total Quality of Recovery-15 (QoR-15) score at 24 hours after the procedure. Secondary outcomes include postoperative pain scores at different time points, total ciprofol consumption, recovery time, post-anesthesia care unit stay, respiratory and hemodynamic adverse events, postoperative nausea and vomiting, and serious adverse events.

The study is expected to provide clinical evidence on the postoperative recovery quality and safety of these two analgesic regimens for patients undergoing ERCP under non-intubated anesthesia.

연구 개요

연구 유형

중재적

등록 (추정된)

180

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Henan
      • Xinxiang, Henan, 중국
        • 모병
        • The First Affiliated Hospital of Henan Medical University

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

**Inclusion Criteria:**

  1. Aged 18 to 80 years;
  2. American Society of Anesthesiologists (ASA) physical status I to III;
  3. Patients scheduled to undergo elective endoscopic retrograde cholangiopancreatography (ERCP).

**Exclusion Criteria:**

  1. Pregnancy or lactation;
  2. Obstructive sleep apnea (OSA);
  3. Long-term use of analgesics or psychotropic drugs, or a history of drug abuse;
  4. Coagulation dysfunction, bleeding tendency, or current anticoagulant therapy;
  5. Allergy to any of the study drugs;
  6. Severe cardiac, hepatic, renal, or other major organ diseases;
  7. Mental or cognitive impairment that prevents cooperation with the assessment;
  8. Inability to comply with the study protocol or complete follow-up;
  9. Requirement for tracheal intubation, postoperative transfer to the intensive care unit (ICU), or postoperative pancreatitis.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Anricofen(HSK21542) 1 μg/kg + Ciprofol

Anricofen (HSK21542) is a peripherally restricted κ-opioid receptor agonist. In this study, it is administered intravenously at a dose of 1 μg/kg 3 minutes before ciprofol induction by slow injection.

Ciprofol is an intravenous sedative agent used for anesthesia induction and maintenance in this study. It is administered intravenously at an induction dose of 0.3 mg/kg by slow injection over more than 30 seconds. After the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score reaches 3 or below, ERCP is initiated. Anesthesia is maintained with a continuous infusion of ciprofol at 1.0-2.0 mg/kg/h. If patient movement or eye opening occurs during the procedure, an additional bolus of 0.10-0.15 mg/kg may be administered, with an interval of at least 2 minutes between additional doses.

활성 비교기: Sufentanil 0.1 μg/kg + Ciprofol

Ciprofol is an intravenous sedative agent used for anesthesia induction and maintenance in this study. It is administered intravenously at an induction dose of 0.3 mg/kg by slow injection over more than 30 seconds. After the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score reaches 3 or below, ERCP is initiated. Anesthesia is maintained with a continuous infusion of ciprofol at 1.0-2.0 mg/kg/h. If patient movement or eye opening occurs during the procedure, an additional bolus of 0.10-0.15 mg/kg may be administered, with an interval of at least 2 minutes between additional doses.

Sufentanil is an opioid analgesic. In this study, it is used as the active comparator and administered intravenously at a dose of 0.1 μg/kg 3 minutes before ciprofol induction by slow injection.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Quality of Recovery-15 (QoR-15) Score at 24 Hours Postoperatively
기간: 24 hours after the procedure

The primary outcome is the total score of the Quality of Recovery-15 (QoR-15) questionnaire at 24 hours after ERCP. The QoR-15 is a patient-reported measure of postoperative recovery quality, with total scores ranging from 0 to 150. Higher scores indicate better postoperative recovery quality.

24 hours after the procedure

2차 결과 측정

결과 측정
측정값 설명
기간
Resting Numerical Rating Scale (NRS) Pain Score
기간: At prespecified time points postoperatively

Resting pain intensity will be assessed using the Numerical Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain), at the prespecified postoperative assessment time points.

At prespecified time points postoperatively
Total Ciprofol Consumption
기간: During the ERCP procedure

The total dose of ciprofol administered to each participant during the ERCP procedure will be recorded and compared between the two groups.

During the ERCP procedure
Respiratory and Hemodynamic Adverse Events
기간: During the procedure and up to 24 hours postoperatively

The incidence and details of perioperative respiratory and hemodynamic adverse events will be recorded. Respiratory events include hypoxemia, apnea or significant hypoventilation, airway interventions, mask-assisted ventilation, supraglottic airway placement, and emergency tracheal intubation. Hemodynamic events include hypotension, bradycardia, and the use of vasoactive drugs such as norepinephrine or atropine.

During the procedure and up to 24 hours postoperatively
Postoperative Nausea and Vomiting (PONV)
기간: Within 24 hours postoperatively

The occurrence of postoperative nausea and vomiting will be recorded and compared between the two groups.

Within 24 hours postoperatively
Serious Adverse Events (SAEs)
기간: From enrollment until the end of the study

The occurrence, type, and details of serious adverse events will be recorded throughout the study period.

From enrollment until the end of the study
Recovery Time
기간: From the end of the ERCP procedure to recovery

The time required for participants to recover from anesthesia after the ERCP procedure will be recorded and compared between the two groups.

From the end of the ERCP procedure to recovery
Post-Anesthesia Care Unit (PACU) Length of Stay
기간: From PACU admission to PACU discharge

The duration of stay in the post-anesthesia care unit (PACU) after the procedure will be recorded and compared between the two groups.

From PACU admission to PACU discharge

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 1월 1일

기본 완료 (추정된)

2028년 3월 1일

연구 완료 (추정된)

2028년 5월 1일

연구 등록 날짜

최초 제출

2026년 1월 16일

QC 기준을 충족하는 최초 제출

2026년 1월 26일

처음 게시됨 (실제)

2026년 1월 29일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 9일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 5일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다